Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SP

WKN: A2ALUN | ISIN: SE0008241491 | Ticker: 8F8
Tradegate
11.11.26 | 13:18
1,354 Euro
+13,40 % +0,160
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SYNACT PHARMA AB Chart 1 Jahr
5-Tage-Chart
SYNACT PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,2701,28217:20
1,2641,28017:16
ACCESS Newswire
120 Leser
Artikel bewerten:
(0)

SynAct Pharma CEO has Acquired Shares in the Company

LUND, SE / ACCESS Newswire / November 16, 2026 / SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm:SYNACT), a clinical-stage biotechnological company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that its CEO, Jeppe Øvlesen, has acquired 20,313 shares in the company.

"SynAct has an exciting future ahead, and I am very confident in the potential we are building. My investment reflects my strong belief in the company's potential and my long-term commitment to SynAct," said CEO Jeppe Øvlesen.

The shares were acquired on Nasdaq Stockholm.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

Investors and Media
Mary-Ann Chang, Cohesion Bureau
E-mail: synactpharma@cohesionbureau.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company pioneering pro-resolution therapies for inflammation through selective activation of the melanocortin system. Its lead asset, resomelagon (AP1189), is a once-daily oral, first-in-class biased agonist of the MC1 and MC3 melanocortin receptors, that has completed Phase 2b development in rheumatoid arthritis, and is in Phase 2 development as host-directed therapy to treat inflammation caused by infections, including respiratory viral infection and dengue. Behind resomelagon, SynAct is building a broad portfolio of oral small molecule and injectable peptide melanocortin agonists designed to induce anti-inflammatory pro-resolution activity, helping patients restore immune balance. For more information, please visit www.synactpharma.com.

Attachments
SynAct Pharma CEO has acquired shares in the company

SOURCE: SynAct Pharma



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/synact-pharma-ceo-has-acquired-shares-in-the-company-1251773

© 2026 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.